A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

PHASE3RecruitingINTERVENTIONAL
Enrollment

351

Participants

Timeline

Start Date

March 24, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

June 30, 2025

Conditions
Gastric CancerHER2 Overexpressing Gastric Carcinoma
Interventions
DRUG

RC48-ADC

2.5 mg/kg IV every 2 weeks

DRUG

Paclitaxel injection

Administered according to label, as one option for Physician's Choice (determined before randomization)

DRUG

Irinotecan Hydrochloride Injection

Administered according to label, as one option for Physician's Choice (determined before randomization)

DRUG

Apatinib Mesylate Tablets

Administered according to label, as one option for Physician's Choice (determined before randomization)

Trial Locations (52)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

Unknown

RECRUITING

Affiliated Hospital of Hebei University, Baoding

RECRUITING

China-Japan Friendship Hospital, Beijing

RECRUITING

Luhe Hospital Affiliated to Capital Medical University, Beijing

RECRUITING

Peking University People's Hospital, Beijing

RECRUITING

Jilin Provincial Tumor Hospital, Changchun

RECRUITING

Xiangya Hospital of Central South University, Changsha

RECRUITING

Affiliated Hospital of Chengde Medical College, Chengde

RECRUITING

Three Gorges Hospital Affiliated to Chongqing University, Chongqing

RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

RECRUITING

Southern Hospital of Southern Medical University, Guangzhou

RECRUITING

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

RECRUITING

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

RECRUITING

First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

RECRUITING

Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

RECRUITING

The Affiliated Tumor Hospital of Harbin Medical University, Harbin

RECRUITING

Anhui Cancer Hospital, Hefei

RECRUITING

Anhui Provincial Hospital, Hefei

RECRUITING

Jinan Central Hospital, Jinan

RECRUITING

Shandong Cancer Hospital, Jinan

RECRUITING

Affiliated Hospital of Jining Medical College, Jining

RECRUITING

The First People's Hospital of Jining City, Jining

RECRUITING

Lanzhou University Second Hospital, Lanzhou

RECRUITING

Linyi Tumor Hospital, Linyi

RECRUITING

Drum Tower Hospital Affiliated to Nanjing University School of Medicine, Nanjing

RECRUITING

Jiangsu Cancer Hospital, Nanjing

RECRUITING

The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital), Nanjing

RECRUITING

Qingdao University Hospital, Qingdao

RECRUITING

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

RECRUITING

Shanghai Changhai Hospital, Shanghai

RECRUITING

Zhongshan Hospital Affiliated to Fudan University, Shanghai

RECRUITING

Cancer Hospital Affiliated to Shantou University Medical College, Shantou

RECRUITING

Liaoning Cancer Hospital, Shenyang

RECRUITING

Shenzhen People's Hospital, Shenzhen

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

RECRUITING

Shanxi Cancer Hospital, Taiyuan

RECRUITING

Tianjin Cancer Hospital, Tianjin

RECRUITING

Weifang People's Hospital, Weifang

RECRUITING

Weihai Municipal Hospital, Weihai

RECRUITING

Huazhong University of Science Tongji Hospital, Tongji Medical College, Wuhan

RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

RECRUITING

Affiliated Hospital of Qinghai University, Xining

RECRUITING

Qinghai Provincial People's Hospital, Xining

RECRUITING

The First Affiliated Hospital of Xinxiang Medical College, Xinxiang

RECRUITING

Affiliated Hospital of Xuzhou Medical University, Xuzhou

RECRUITING

Xuzhou Central Hospital, Xuzhou

RECRUITING

Subei People's Hospital of Jiangsu Province, Yangzhou

RECRUITING

Yantai Yuhuangding Hospital, Yantai

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT04714190 - A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression | Biotech Hunter | Biotech Hunter